Company Description
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Amro Albanna |
Contact Details
Address: 737 North Fifth Street, Suite 200 Richmond, Virginia 23219 United States | |
| Phone | 650 870 1200 |
| Website | aditxt.com |
Stock Details
| Ticker Symbol | ADTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001726711 |
| CUSIP Number | 007025109 |
| ISIN Number | US0070256047 |
| Employer ID | 82-3204328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amro A. Albanna | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary and Director |
| Thomas J. Farley CPA | Chief Financial Officer |
| Corinne D. Pankovcin CPA, M.B.A. | Chief Mergers and Acquisitions Officer |
| Rowena Albanna | Chief Operating Officer |
| Jennifer Lee | Director of Human Resources |
| Dr. Dolly B. Tyan D(ABHI), Ph.D. | Senior Vice President of Clinical Development ? Transplantation |
| Ge Chen M.D., M.S. | Senior Vice President of Preclinical Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 8-K | Current Report |
| Dec 6, 2024 | PRE 14A | Other preliminary proxy statements |
| Nov 21, 2024 | 8-K/A | [Amend] Current report |
| Nov 21, 2024 | 8-K/A | [Amend] Current report |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 5, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |